期刊文献+

西格列汀与沙格列汀治疗2型糖尿病的疗效对比研究 被引量:3

The Comparative Study of the Efficacy of Sitagliptin and Saxagliptin Treating Type 2 Diabetes
下载PDF
导出
摘要 目的:比较西格列汀与沙格列汀治疗2型糖尿病的疗效。方法:将50例门诊初次确诊为2型糖尿病的患者随机分为西格列汀组和沙格列汀组各25例,分别用西格列汀或沙格列汀治疗12周,观察患者BMI、FPG、2 hPG、HbA1c等指标变化及低血糖发生情况。结果:治疗后两组FPG、2 hPG、HbA1c较治疗前均有明显下降,有统计学意义(P<0.01),BMI较治疗前均有轻度下降,但无统计学意义(P>0.05);两组间BMI、HbA1c、FPG、2 hPG、低血糖发生率等指标相比较无统计学意义(P>0.05)。结论:西格列汀及沙格列汀均能有效地控制2型糖尿病患者的血糖,轻度减轻体重,且低血糖发生率较低,但两者的疗效无明显差别。 Objective: To compare the efficacy of sitagliptin and saxagliptin treating type 2 diabetes. Methods: 50 Patients initially diagnosed as outpatients with type 2 diabetes were randomly assigned to sitagliptin group and saxagliptin group, each group had 25 patients, treated with sitagliptin or saxagliptin for 12 weeks respectively. Then observe the index changes of BMI, FPG, 2 hPG, HbA1 c and the incidences of hypoglycemia. Results: After treatment, FPG, 2 hPG, HbA1 c were significantly reduced compared with before in both groups(P0.01), BMI had decreased slightly compared with before in both groups(P0.05). Little changes were found between sitagliptin group and saxagliptin group on BMI, HbA1 c, FPG, 2 hPG and other indicators(P0.05). Conclusion: Sitagliptin and saxagliptin can effectively decrease blood sugar in patients with type 2 diabetes, reduce weight lightly, and the incidence of hypoglycemia is very low.There is no difference on the efficacy between sitagliptin group and saxagliptin group.
出处 《实用中西医结合临床》 2014年第6期11-12,共2页 Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine
关键词 2型糖尿病 低血糖发生率 西格列汀 沙格列汀 Type 2 diabetes Incidence of hypoglycemia Sitagliptin Saxagliptin
  • 相关文献

参考文献8

二级参考文献32

  • 1周琼,欧阳金芝,张木勋,张建华,杨雁.胰升糖素样肽-1对高游离脂肪酸诱导的胰岛β细胞凋亡作用的研究[J].临床内科杂志,2007,24(4):275-277. 被引量:2
  • 2Drucker DJ,Nauck MA. The incretin system:glucagonlike peptide-1 re- ceptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet,2006,368 : 1696-1705.
  • 3Salehi M, Aulinger BA, D'Alessio DA. Targeting 13-cell mass in type 2 diabetes:promise and limetations of new drugs based on incretins. En- doer Rev ,2008,29:367-379.
  • 4Mannucci E,Tesi F,Bardini G,et al. Effects of mefformin on glucagon- like peptide-1 levels in obese patients with and without Type 2 diabe- tes. Diabetes Nutr Metab,2004,17:336-342.
  • 5Yasuda N, Inoue T, Nagakura T, et al. Enhanced secretion of glucagon- like peptide 1 by biguanide compounds. Bioehem Biophys Res Com- mun ,2002,298:779-784.
  • 6Knop FK. Reduced incretin effect in type 2 diabetes:cause or conse- quence of the diabetic state? Diabetes,2007,56:1951-1959.
  • 7Rosenstock J, Foley JE, Rendell M, et al. Effects of the dipeptidyl pepti- dase-IV inhibitor vildagliptin on incretin hormones. Islet function, and postprandial glyeemia in subjects with impaired glucose tolerance. Dia- betes care ,2008,31:30-35.
  • 8Bergman AJ,Cote J,Maes A,et al. Sitagliptin(MK-0431),a selective dipeptidyl-peptidase-IV (DPP-4) inhibitor, does not affect the pharmacokinetics of simvastatin in humans. Clin Pharmacol Ther, 2005,79: 48.
  • 9Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitaglipt in monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract, 2008,79 : 291-298.
  • 10Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabectologia, 2007,50 : 1148-1155.

共引文献151

同被引文献21

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部